MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours

British Journal of Cancer

Volumn 114, Issue 8, 2016, Pages 917-928

  Green, Andrew R ^a   Aleskandarany, Mohammed A ^b   Agarwal, Devika ^c   Elsheikh, Somaia ^a,b   Nolan, Christopher C ^a   Diez Rodriguez, Maria ^a   Macmillan, R Douglas ^b   Ball, Graham R ^c   Caldas, Carlos ^d   Madhusudan, Srinivasan ^a   Ellis, Ian O ^a,b   Rakha, Emad A ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

basal like; Breast cancer; luminal; MYC; prognosis; triple negative

Indexed keywords

CYCLIN B1; KI 67 ANTIGEN; MESSENGER RNA; MYC PROTEIN; ATM PROTEIN; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER HORMONE THERAPY; CANCER RESISTANCE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISTANT METASTASIS FREE SURVIVAL; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; AGED; BREAST TUMOR; DISEASE FREE SURVIVAL; DRUG RESISTANCE; ENDOCRINE CELL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PROGNOSIS;

AGED; ATAXIA TELANGIECTASIA MUTATED PROTEINS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CYCLIN B1; CYCLIN E; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; ENDOCRINE CELLS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, ERBB-2; RNA, MESSENGER;

EID: 84960192910     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.46     Document Type: Article

References (78)

1. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO. (2005). High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116: 340-350
2. Abdel-Fatah TM, Russell R, Agarwal D, Moseley P, Abayomi MA, Perry C, Albarakati N, Ball G, Chan S, Caldas C, Ellis IO, Madhusudan S. (2014). DNA polymerase beta deficiency is linked to aggressive breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts. Mol Oncol 8: 520-532
3. Adem C, Soderberg CL, Hafner K, Reynolds C, Slezak JM, Sinclair CS, Sellers TA, Schaid DJ, Couch F, Hartmann LC, Jenkins RB. (2004). ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes Chromosomes Cancer 41: 1-11
4. Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, Neve RM, Kuo WL, Sorlie T, Sahin A, Valero V, Keyomarsi K, Gray JW, Borresen-Dale AL, Mills GB, Hennessy BT. (2009). Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 15: 3654-3662
5. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Kochli O, Zuber M, Dieterich H, Mross F, Wilber K, Simon R, Sauter G. (2004). Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 64: 8534-8540
6. Albihn A, Johnsen JI, Henriksson MA. (2010). MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res 107: 163-224
7. Aleskandarany MA, Green AR, Benhasouna AA, Barros FF, Neal K, Reis-Filho JS, Ellis IO, Rakha EA. (2012). Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res 14: R3
8. Aleskandarany MA, Green AR, Rakha EA, Mohammed RA, Elsheikh SE, Powe DG, Paish EC, Macmillan RD, Chan S, Ahmed SI, Ellis IO. (2010a). Growth fraction as a predictor of response to chemotherapy in nodenegative breast cancer. Int J Cancer 126: 1761-1769
9. Aleskandarany MA, Rakha EA, Ahmed MA, Powe DG, Ellis IO, Green AR. (2011). Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer. Breast Cancer Res Treat 127: 407-416
10. Aleskandarany MA, Rakha EA, Ahmed MA, Powe DG, Paish EC, Macmillan RD, Ellis IO, Green AR. (2010b). PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Res Treat 122: 45-53
11. Alevizopoulos K, Vlach J, Hennecke S, Amati B. (1997). Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins. EMBO J 16: 5322-5333
12. Arango D, Corner GA, Wadler S, Catalano PJ, Augenlicht LH. (2001). c-Myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res 61: 4910-4915
13. Aulmann S, Adler N, Rom J, Helmchen B, Schirmacher P, Sinn H.P. (2006). cmyc amplifications in primary breast carcinomas and their local recurrences. J Clin Pathol 59: 424-428
14. Barratt PL, Seymour MT, Stenning SP, Georgiades I, Walker C, Birbeck K, Quirke P. UKCCCR. Axis Trial Collaborators; Adjuvant X-ray and Fluorouracil Infusion Study. (2002). DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 360: 1381-1391
15. Barros FF, Abdel-Fatah TM, Moseley P, Nolan CC, Durham AC, Rakha EA, Chan S, Ellis IO, Green AR. (2014). Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay. Breast Cancer Res Treat 144: 273-285
16. Berns EM, Foekens JA, Van Putten WL, Van Staveren IL, Portengen H, de Koning WC, Klijn JG. (1992a). Prognostic factors in human primary breast cancer: comparison of c-myc and HER2/neu amplification. J Steroid Biochem Mol Biol 43: 13-19
17. Berns EM, Klijn JG, van Putten WL, van Staveren IL, Portengen H, Foekens JA. (1992b). c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 52: 1107-1113
18. Boddupally PV, Hahn S, Beman C, De B, Brooks TA, Gokhale V, Hurley LH. (2012). Anticancer activity and cellular repression of c-MYC by the G-quadruplex-stabilizing 11-piperazinylquindoline is not dependent on direct targeting of the G-quadruplex in the c-MYC promoter. J Med Chem 55: 6076-6086
19. Borg A, Baldetorp B, Ferno M, Olsson H, Sigurdsson H. (1992). c-myc amplification is an independent prognostic factor in postmenopausal breast cancer. Int J Cancer 51: 687-691
20. Cancer Genome Atlas Network. (2012). Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70
21. Carroll JS, Swarbrick A, Musgrove EA, Sutherland RL. (2002). Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Res 62: 3126-3131
22. Chen Z, Wang Y, Warden C, Chen S. (2015). Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells. J Steroid Biochem Mol Biol 149: 118-127
23. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, Mckinney S, Group M, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale AL, Brenton JD, Tavare S, Caldas C, Aparicio S. (2012). The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 486: 346-352
24. Dang CV. (2012). MYC on the path to cancer. Cell 149: 22-35
25. Deming SL, Nass SJ, Dickson RB, Trock BJ. (2000). C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 83: 1688-1695
26. Dublin EA, Patel NK, Gillett CE, Smith P, Peters G, Barnes DM. (1998). Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. Int J Cancer 79: 71-75
27. Elsheikh S, Green AR, Aleskandarany MA, Grainge M, Paish CE, Lambros MB, Reis-Filho JS, Ellis IO. (2008). CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat 109: 325-335
28. Gewirtz DA, Randolph JK, Chawla J, Orr MS, Fornari FA. (1998). Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxydaunorubicin) in the MCF-7 breast tumor cell line. Cancer Chemother Pharmacol 41: 361-369
29. Gray-Bablin J, Zalvide J, Fox MP, Knickerbocker CJ, Decaprio JA, Keyomarsi K. (1996). Cyclin E, a redundant cyclin in breast cancer. Proc Natl Acad Sci USA 93: 15215-15220
30. Guerra L, Albihn A, Tronnersjo S, Yan Q, Guidi R, Stenerlow B, Sterzenbach T, Josenhans C, Fox JG, Schauer DB, Thelestam M, Larsson LG, Henriksson M, Frisan T. (2010). Myc is required for activation of the ATMdependent checkpoints in response to DNA damage. PLoS One 5: e8924
31. Habashy HO, Rakha EA, Ellis IO, Powe DG. (2013). The oestrogen receptor coactivator CARM1 has an oncogenic effect and is associated with poor prognosis in breast cancer. Breast Cancer Res Treat 140: 307-316
32. Han S, Ahn SH, Park K, Bae BN, Kim KH, Kim HJ, Kim YD, Kim HY. (2001). P16INK4a protein expression is associated with poor survival of the breast cancer patients after CMF chemotherapy. Breast Cancer Res Treat 70: 205-212
33. Hernandez-Vargas H, Ballestar E, Carmona-Saez P, Von Kobbe C, Banon-Rodriguez I, Esteller M, Moreno-Bueno G, Palacios J. (2006). Transcriptional profiling of MCF7 breast cancer cells in response to 5-Fluorouracil: relationship with cell cycle changes and apoptosis, and identification of novel targets of p53. Int J Cancer 119: 1164-1175
34. Horiuchi D, Anderton B, Goga A. (2014). Taking on challenging targets: making MYC druggable. Am Soc Clin Oncol Educ Book e497-e502; doi: 10.14694/EdBook-AM.2014.34.e497
35. Hothorn T, Hornik K, Zelis A. (2006). Unbiased recursive partitioning: a conditional inference framework. J Comput Graphical Stat 15: 651-674
36. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, Perou CM. (2006). The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7: 96
37. Janocko LE, Brown KA, Smith CA, Gu LP, Pollice AA, Singh SG, Julian T, Wolmark N, Sweeney L, Silverman JF, Shackney SE. (2001). Distinctive patterns of Her-2/neu, c-myc, and cyclin D1 gene amplification by fluorescence in situ hybridization in primary human breast cancers. Cytometry 46: 136-149
38. Jezequel P, Campone M, Gouraud W, Guerin-Charbonnel C, Leux C, Ricolleau G, Campion L. (2012). bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat 131: 765-775
39. Knudsen ES, Mcclendon AK, Franco J, Ertel A, Fortina P, Witkiewicz AK. (2015). RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer. Cell Cycle 14: 109-122
40. Lancashire LJ, Powe DG, Reis-Filho JS, Rakha E, Lemetre C, Weigelt B, Abdel-Fatah TM, Green AR, Mukta R, Blamey R, Paish EC, Rees RC, Ellis IO, Ball GR. (2010). A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks. Breast Cancer Res Treat 120: 83-93
41. Li B, Simon MC. (2013). Molecular pathways: targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer. Clin Cancer Res 19: 5835-5841
42. Liao DJ, Dickson RB. (2000). c-Myc in breast cancer. Endocr Relat Cancer 7: 143-164
43. Liao DJ, Natarajan G, Deming SL, Jamerson MH, Johnson M, Chepko G, Dickson RB. (2000). Cell cycle basis for the onset and progression of c-Myc-induced, TGFalpha-enhanced mouse mammary gland carcinogenesis. Oncogene 19: 1307-1317
44. Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A, Yang J, Semaan DJ, Chen C, Fox EA, Gray NS, Monahan J, Schlegel R, Beroukhim R, Mills GB, Zhao JJ. (2011). Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathwayindependent mechanisms. Nat Med 17: 1116-1120
45. McNeil CM, Sergio CM, Anderson LR, Inman CK, Eggleton SA, Murphy NC, Millar EK, Crea P, Kench JG, Alles MC, Gardiner-Garden M, Ormandy CJ, Butt AJ, Henshall SM, Musgrove EA, Sutherland RL. (2006). c-Myc overexpression and endocrine resistance in breast cancer. J Steroid Biochem Mol Biol 102: 147-155
46. Mcshane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. (2005). REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93: 387-391
47. Miura S, Nakashima M, Ito M, Kondo H, Meirmanov S, Hayashi T, Soda M, Matsuo T, Sekine I. (2008). Significance of HER2 and C-MYC oncogene amplifications in breast cancer in atomic bomb survivors: associations with radiation exposure and histologic grade. Cancer 112: 2143-2151
48. Musgrove EA, Sergio CM, Loi S, Inman CK, Anderson LR, Alles MC, Pinese M, Caldon CE, Schutte J, Gardiner-Garden M, Ormandy CJ, Mcarthur G, Butt AJ, Sutherland RL. (2008). Identification of functional networks of estrogen-and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS One 3: e2987
49. Naidu R, Wahab NA, Yadav M, Kutty MK. (2002). Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction. Int J Mol Med 9: 189-196
50. Nair R, Roden DL, Teo WS, Mcfarland A, Junankar S, Ye S, Nguyen A, Yang J, Nikolic I, Hui M, Morey A, Shah J, Pfefferle AD, Usary J, Selinger C, Baker LA, Armstrong N, Cowley MJ, Naylor MJ, Ormandy CJ, Lakhani SR, Herschkowitz JI, Perou CM, Kaplan W, O toole SA, Swarbrick A. (2014). c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. Oncogene 33: 3992-4002
51. Nass SJ, Dickson RB. (1997). Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res Treat 44: 1-22
52. Nemtsova MV, Zemliakova VV, Kuznetsova EV, Babenko OV, Zavalishina LE, Andreeva I, Bateva MV, Frank GA, Zaletaev DV. (2007). [Analysis of the correlation between genetic and immunohistochemical markers (RB1, p16 and p53 gene regultors of a cell cycle) in sporadic mammary gland carcinoma]. Arkh Patol 69: 3-6
53. Palaskas N, Larson SM, Schultz N, Komisopoulou E, Wong J, Rohle D, Campos C, Yannuzzi N, Osborne JR, Linkov I, Kastenhuber ER, Taschereau R, Plaisier SB, Tran C, Heguy A, Wu H, Sander C, Phelps ME, Brennan C, Port E, Huse JT, Graeber TG, Mellinghoff IK. (2011). 18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res 71: 5164-5174
54. Patel JH, Loboda AP, Showe MK, Showe LC, Mcmahon SB. (2004). Analysis of genomic targets reveals complex functions of MYC. Nat Rev Cancer 4: 562-568
55. Planas-Silva MD, Bruggeman RD, Grenko RT, Smith JS. (2007). Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer. Exp Mol Pathol 82: 85-90
56. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. (2007). Prognostic markers in triple-negative breast cancer. Cancer 109: 25-32
57. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO. (2009). Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15: 2302-2310
58. Reis-Filho JS, Milanezi F, Carvalho S, Simpson PT, Steele D, Savage K, Lambros MB, Pereira EM, Nesland JM, Lakhani SR, Schmitt FC. (2005). Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res 7: R1028-R1035
59. Robanus-Maandag EC, Bosch CA, Kristel PM, Hart AA, Faneyte IF, Nederlof PM, Peterse JL, van de Vijver MJ. (2003). Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. J Pathol 201: 75-82
60. Rodriguez-Pinilla SM, Jones RL, Lambros MB, Arriola E, Savage K, James M, Pinder SE, Reis-Filho JS. (2007). MYC amplification in breast cancer: a chromogenic in situ hybridisation study. J Clin Pathol 60: 1017-1023
61. Roux-Dosseto M, Romain S, Dussault N, Desideri C, Piana L, Bonnier P, Tubiana N, Martin PM. (1992). c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse. Eur J Cancer 28A: 1600-1604
62. Ruggero D. (2009). The role of Myc-induced protein synthesis in cancer. Cancer Res 69: 8839-8843
63. Rummukainen JK, Salminen T, Lundin J, Kytola S, Joensuu H, Isola JJ. (2001). Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array. Mod Pathol 14: 1030-1035
64. Santos GF, Scott GK, Lee WM, Liu E, Benz C. (1988). Estrogen-induced post-transcriptional modulation of c-myc proto-oncogene expression in human breast cancer cells. J Biol Chem 263: 9565-9568
65. Schlotter CM, Vogt U, Bosse U, Mersch B, Wassmann K. (2003). C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res 5: R30-R36
66. Schmitt FC, Reis-Filho JS. (2002). Oncogenes, granules and breast cancer: what has c-myc to do with apocrine changes? Breast 11: 463-465
67. Shajahan-Haq AN, Cook KL, Schwartz-Roberts JL, Eltayeb AE, Demas DM, Warri AM, Facey CO, Hilakivi-Clarke LA, Clarke R. (2014). MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer. Mol Cancer 13: 239
68. Shanmugham R, Gopalan R, Shanthi P, Krishnan KB. (2004). Tumour angiogenesis and C-myc expression in breast carcinomas. Indian J Pathol Microbiol 47: 340-342
69. Shen L, O shea JM, Kaadige MR, Cunha S, Wilde BR, Cohen AL, Welm AL, Ayer DE. (2015). Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Proc Natl Acad Sci USA 112: 5425-5430
70. Sherr CJ. (1996). Cancer cell cycles. Science 274: 1672-1677
71. Sierra A, Castellsague X, Escobedo A, Moreno A, Drudis T, Fabra A. (1999). Synergistic cooperation between c-Myc and Bcl-2 in lymph node progression of T1 human breast carcinomas. Breast Cancer Res Treat 54: 39-45
72. Smoot M, Ono K, Ideker T, Maere S. (2011). PiNGO: a Cytoscape plugin to find candidate genes in biological networks. Bioinformatics 27: 1030-1031
73. Spandidos DA, Yiagnisis M, Papadimitriou K, Field JK. (1989). ras, c-myc and c-erbB-2 oncoproteins in human breast cancer. Anticancer Res 9: 1385-1393
74. Spaventi R, Kamenjicki E, Pecina N, Grazio S, Grazio S, Pavelic J, Kusic B, Cvrtila D, Danilovic Z, Spaventi S. (1994). Immunohistochemical detection of TGF-alpha, EGF-R, c-erbB-2, c-H-ras, c-myc, estrogen and progesterone in benign and malignant human breast lesions: a concomitant expression. In Vivo 8: 183-189
75. Venditti M, Iwasiow B, Orr FW, Shiu RP. (2002). C-myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells. Int J Cancer 99: 35-42
76. Vita M, Henriksson M. (2006). The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 16: 318-330
77. Wahlstrom T, Arsenian Henriksson M. (2015). Impact of MYC in regulation of tumor cell metabolism. Biochim Biophys Acta 1849: 563-569
78. Xu J, Chen Y, Olopade OI. (2010). MYC and breast cancer. Genes Cancer 1: 629-640